Pharma Major Lupin announced today that it has received final approval for its Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration (FDA) to market generic version of Benicars tablets, 5 mg, 20 mg and 40 mg.

Lupin's Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg are the AS rated generic equivalent of Daiichi Sankyo Inc.'s Benicar tablets. It is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure.

Benicare tablets had US sales of USD 1,036 million (IMS MAT December 2016).

Shares of the company gained Rs 0.5, or 0.04%, to trade at Rs 1,337.75. The total volume of shares traded was 146,893 at the BSE (3.06 p.m., Friday).